MOBIDIAG-LTD.
Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces the CE-IVD marking of the Novodiag® Stool Parasites test, a comprehensive and cost-effective molecular diagnostic test for the detection of intestinal parasites directly from stool samples.
Tuomas Tenkanen, CEO of Mobidiag, said, “Parasitic diseases contribute significantly to the burden of infectious diseases worldwide and current diagnostic methods such as microscopy are labor-intensive and require a high level of skill. Our Novodiag® Stool Parasites test is the only fully automated, rapid, cost-effective and easy to use diagnostic solution that can identify a comprehensive range of parasitic targets, for use in laboratories and hospitals.”
“Novodiag® Stool Parasites is the fourth test on our Novodiag® platform and, together with our Novodiag® C. difficile , Novodiag® Bacterial GE+ and Novodiag® CarbaR+ tests, further strengthens our offering in the detection of gastrointestinal infections. With our complementary Amplidiag® and Novodiag® solutions, we continue to offer a range of highly versatile combined solutions enabling the broad application of molecular diagnostics around the world.”
Novodiag® Stool Parasites combines real-time PCR and microarray technologies to allow cost-effective, rapid and comprehensive detection of >95% of intestinal parasites. This syndromic test is designed to run on-demand using the automated Novodiag® system and is able to detect the presence of nucleic acid markers corresponding to the identification of the most common protozoan, helminths, and microsporidia from stool samples. The test provides complete results in 90 minutes with less than five minutes hands-on time by an operator.
While most infections and death from parasitic diseases affect people in developing countries, increasing incidence in developed nations combined with a shortage of microscopy trained hospital staff are driving demand for this test.
The Novodiag® Stool Parasites test is now available directly through Mobidiag and local distributors. For more information, visit https://mobidiag.com/products/novodiag/#stoolparasites
About Novodiag®
Stool Parasites
Novodiag®
Stool Parasites is an automated qualitative nucleic acid-based diagnostic test for detecting the presence of nucleic acid markers corresponding to the identification of the most common protozoan, helminths, and microsporidia from stool samples. It is part of the Novodiag®
platform, Mobidiag’s fully automated molecular testing platform for diagnostics of infectious diseases and antibiotic resistances. Combining real-time PCR and microarray technologies, Novodiag®
platform allows direct analysis of a patient sample placed in a disposable cartridge for comprehensive screening of multiple or single pathogens. In addition of Novodiag®
C. difficile
, Novodiag®
Bacterial GE+ and Novodiag®
CarbaR+, we launch a new test, the Novodiag®
Stool Parasites which complements our offer for gastrointestinal infections. Our panel covers >95% of stool parasites.
About Mobidiag Ltd.
Mobidiag is a revenue generating, fast growing molecular diagnostics company with complementary platform technologies that can meet the differing diagnostic needs for customers in multiple healthcare settings. Initially designed for ease of use and adaptability for large scale manufacturing, Mobidiag’s Amplidiag®
and Novodiag®
platforms provide a combination of high quality and affordability, allowing for widespread applicability for both mass screening and highly specific syndromic testing in multiple indications. The Company’s highly versatile product offering enables the broad application of molecular diagnostics to address the global challenge of antimicrobial resistance and other unmet diagnostic needs. Mobidiag’s intial focus has been on gastrointestinal diseases and superbugs, through direct sales and distributors, and is rapidly building a leading position in European markets.
Mobidiag has more than 100 staff and is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191008005570/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
China’s Top Baijiu Brand Moutai Showcases China's Green Progress in Manufacturing at COP3015.11.2025 17:41:00 CET | Press release
On November 10 local time, the 30th United Nations Climate Change Conference (COP30) opened in Belem, a city in northern Brazil. As one of the activities at the China Pavilion of COP30, the Side Event on Ecological Civilization and Beautiful China Practice was held simultaneously, focusing on ecological civilization, sharing China's experience, and building global consensus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114596036/en/ China Pavilion at COP30 in Belem, Brazil. Addressing the topic of green transformation in traditional industries, You Yalin, Deputy Party Secretary of Kweichow Moutai Co., Ltd., shared the company's green transformation practices and experiences from the perspective of a traditional Chinese liquor producer. “We hope that every bottle of Moutai not only delivers a feast of flavor, but also conveys the idea of harmony between humans and nature. We aim to contribute China's wisdom and Moutai's
Andersen Consulting styrker sine kompetencer inden for digital transformation med Criticalcase14.11.2025 19:44:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer gennem en samarbejdsaftale med Criticalcase, der er et europæisk firma med speciale i cloud-infrastruktur, cybersikkerhed og administrerede it-tjenester. Criticalcase blev grundlagt i 1999 og har hovedsæde i Italien og har markeret sig inden for cloud-sektoren ved at designe og vedligeholde komplekse infrastrukturer for mellemstore og store virksomheder. Gennem skræddersyede løsninger tilbyder virksomheden et omfattende udvalg af tjenester, herunder sikkerhed, overvågning døgnet rundt og systemadministration, hvilket skaber pålidelighed, optimal ydeevne og beskyttelse helt ned til operativsystemniveau. "Vores mission har altid været at guide kunder gennem komplekse teknologiske udfordringer med en strategisk og praktisk tilgang," siger Luca Nunno, der er CEO for Criticalcase. "Samarbejdet med Andersen Consulting giver os mulighed for at få vores ekspertise ud til et bredere globalt publikum og skabe værdi gennem innovation og digital ekspert
Andersen Consulting samarbejder med TruScore14.11.2025 16:15:00 CET | Pressemeddelelse
Andersen Consulting annoncerer en samarbejdsaftale med TruScore, som styrker virksomhedens kompetencer inden for humankapital og hjælper kunder med at opbygge stærkere ledelsesteams og organisatoriske kulturer. Truscore, der har hovedsæde i USA, specialiserer sig i at levere fuldt skræddersyede survey-hosting-løsninger, der gør det muligt for organisationer at gennemføre whitelabel-vurderingsordninger, der er skalerbare, sikre og tilpasset deres specifikke behov. TruScore tilbyder avancerede 360-graders feedbackløsninger og samarbejder med Fortune 500-virksomheder, ledelsesudviklingsfirmaer og uafhængige coaches om at designe og administrere deres egne vurderingsplatforme og -oplevelser. "I nutidens dynamiske forretningsmiljø har organisationer brug for mere end blot en strategi – de har brug for stærk og robust ledelse for at kunne omsætte strategien til succes," siger Derek Murphy, CEO for TruScore. "Gennem dette samarbejde med Andersen Consulting kan vi få vores ekspertise inden for
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 13:47:00 CET | Press release
-- Advancing Its Overseas Growth Strategy to Expand Japanese-Quality Aesthetic Medicine Across Asia Following Singapore -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom